BetterLife Pharma (TSE:BETR) has released an update.
BetterLife Pharma has reported promising safety data for its lead drug candidate BETR-001, a non-hallucinogenic LSD derivative, showing no genotoxic effects. This positive outcome brings the company closer to starting clinical trials for this innovative treatment aimed at neuro-psychiatric and neurological disorders. Additionally, BetterLife has issued common shares and warrants through the conversion of its convertible debentures.
For further insights into TSE:BETR stock, check out TipRanks’ Stock Analysis page.
